Introduction
Combined liver-kidney transplantation (CLKT) is performed frequently in patients with cirrhosis with associated kidney diseases. Most of these patients have chronic renal failure due to parenchymal renal diseases, in most cases glomerulopathy associated with alcoholic cirrhosis or with chronic hepatitis B or C infection, or chronic renal failure due to kidney rejection after kidney transplantation [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . CLKT has also been used for patients with cirrhosis and hepatorenal syndrome (HRS), although the use of renal transplantation in this setting is controversial due to the potential reversibility of renal failure after liver transplantation (LT) alone [11] [12] [13] .
Since the introduction of the Model for End-stage Liver Disease (MELD) score system in the USA and other countries, the number of patients treated with CLKT has increased markedly, mainly due to the fact that the presence of renal failure associated with liver disease raises the MELD score and thus increases the likelihood of transplantation [14, 15] . Despite the relatively common use of CLKT in cirrhosis, a number of issues remain poorly understood. Among others, it is not known to what extent the associated renal transplantation affects posttransplantation outcomes in patients with cirrhosis. The existing limited information is due, at least in part, to the fact that most published series of patients treated with CLKT include not only patients with cirrhosis but also a significant number of patients with metabolic diseases, such as primary hyperoxaluria, or polycystic kidney and liver disease [1, 2, 4, 5, 8, 9, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . On this background, the aim of the current study was to assess the survival and postoperative complications of patients with cirrhosis and chronic kidney diseases [30] treated with CLKT in a single institution. To evaluate to what extent the combined kidney transplantation affects posttransplantation outcome compared to LT alone, the outcome of patients with CLKT was compared to that of a group of patients with cirrhosis treated with LT alone matched by age, sex, year of transplantation and severity of cirrhosis.
Materials and methods

Study population
Data from all patients with CLKT performed in the Hospital Clínic (Barcelona, Catalonia, Spain) between December 1994 and December 2004 were retrospectively reviewed. During this period, the criteria to perform a CLKT in our unit were as follows: (i) in patients with previous kidney transplant -existence of chronic kidney disease either requiring haemodialysis or with glomerular filtration rate (GFR) below 30 mL/min associated with decompensated cirrhosis or compensated cirrhosis but with portal hypertension and (ii) in patients without previous kidney transplant -decompensated cirrhosis with chronic kidney disease either requiring haemodialysis or with a serum creatinine >1.5 mg/dL (this latter criterion was later substituted by a GFR below 30 mL/min). These criteria are similar to those that have been proposed in a recent consensus conference [31] . Before transplantation, a renal biopsy was performed to make the diagnosis of the renal disease, unless contraindicated because of severe coagulopathy (prothrombin time <50% and platelet count <50 000 per μ/L). No patient with HRS was treated with CLKT. Patients with liver diseases other than cirrhosis and associated kidney diseases treated with CLKT were excluded from the study.
A group of patients with cirrhosis treated with LT matched by age, year of transplantation and severity of liver disease, as estimated by the ChildPugh score, was also analysed. For each patient treated with CLKT, three matched patients treated with LT alone were analysed. The study was approved by the institutional review board of our centre and included a total of 20 patients treated with CLKT and 60 patients treated with LT alone.
Methods
Data collected from the patient's clinical records were incorporated into a database that included demographic parameters, previous complications of cirrhosis, biochemical parameters measured immediately before transplantation, Child-Pugh score at the time of transplantation, need for dialysis previous to transplantation, comorbidities (such as diabetes mellitus or hypertension), date of transplantation, ABO blood group (ABO) and human leukocyte antigen (HLA) mismatches. Results of cross-matches were also added to the database for analysis, even if they were not used at the time of transplantation. Liver function tests, as well as complete blood count and coagulation tests, were registered at baseline (pretransplantation) and during hospitalisation. Renal function was recorded at baseline, during hospitalisation and at 1, 3, 6, 12 and 36 months after transplantation. MELD score at the time of transplantation was retrospectively calculated for each patient using the standard formula (www.mayoclinic.org/meld/mayomodel6.html). International normalized ratio (INR) was not available in patients transplanted before 1997. In these patients, INR was calculated according to the following formula: (prothrombin time of patient/control prothrombin time)
ISI , ISI being the international sensitivity index for thromboplastin [32] .
Primary end points of the study were 1-and 3-year survival probabilities. Secondary end points were development of complications during the first 6 months after transplantation and outcome of renal function.
The complications analysed were as follows: intraabdominal bleeding, infections, acute rejection, renal failure and side effects of immunosuppressive drugs. Intraabdominal bleeding was assessed during surgery and within the first week posttransplantation, while renal failure, infections, acute rejection and side effects of immunosuppressive drugs were evaluated during the first 6 months after transplantation. In addition, the time spent in the ICU and the total duration of the hospitalisation were also analysed.
Surgical procedure and immunosuppression
Liver and kidney transplantations were performed by experienced surgeons according to standard techniques with preservation of vena cava and without bypass except in three patients. For CLKT, the kidney was inserted after the liver and placed extraperitoneally. Before transplantation, cross-matches were positive in 17% of the CLKT group and in 4% of the LT group (not statistically significant, ns). Immunosuppression was based on calcineurin inhibitors in all patients. All transplanted patients before 2000 received cyclosporine (CsA), while among those transplanted after 2000, 56% received tacrolimus in the LT group compared to 15% in the CLKT group. Six patients (30%) from the CLKT group received an induction therapy (three with thymoglobulin, two with monoclonal antibody muromonab-CD3 (OKT3) and one with monoclonal antibodies directed against interleukine-2 receptor (anti-IL2)). Only four of LT patients (7%) received an induction therapy (anti-IL2 antibodies). Mycophenolate mophetil (MMF) was used more frequently in CLKT patients compared to LT patients (45 vs 17%, P = 0.01). MMF was uncommonly used in LT patients because most of these patients did not have renal failure at the time of transplant. Acute liver or kidney rejection was treated with a similar regimen of steroid pulses in both groups.
Definitions
Renal function. The presence of chronic kidney disease before transplantation was defined by using the criteria of the National Kidney Foundation [30] .
Posttransplant renal function was classified according to the following definitions:
(i) For CLKT patients, acute renal failure (ARF) was defined as an increase of serum creatinine value >50% over the lowest value achieved posttransplantation. In the case of primary dysfunction of the graft, a worsening of renal function or an absence of change from pretransplant serum creatinine value was also considered as ARF;
(ii) For LT patients, ARF was defined as an increase of serum creatinine >50% over the pretransplant value, with a final level >1.5 mg/dL; (iii) For patients with pretransplant normal renal function, complete resolution of ARF was defined as a reduction in serum creatinine to a value <1.5 mg/dL; for patients with pretransplant kidney disease, complete resolution of ARF was defined when serum creatinine decreased to a final value within 25% of the lowest posttransplant value; (iv) Chronic kidney disease was defined using the criteria of the National Kidney Foundation [30] .
Other complications. Selection of donors was based on ABO compatibility, organ size and quality of donor. HLA matching was disregarded. Liver and kidney rejections were diagnosed on the basis of clinical findings and confirmed by a biopsy whenever possible. Liver graft survival was defined as the days of survival with a functioning organ without the need for retransplantation. Renal graft survival was calculated as time elapsed before reaching chronic dialysis or end-stage renal disease as defined by Kidney Disease Outcomes Quality Initiative Guidelines, from the National Kidney Foundation (K/DOQI) stage V (www.kidney.org/professionals/kdoqi/ guidelines) or retransplantation. Infectious complications were defined by the presence of systemic or local signs of infection together with positive cultures and/or compatible radiological findings requiring intravenous administration of antimicrobial agents. Significant hypotension was defined as a systolic blood pressure <80 mm Hg or a mean arterial blood pressure of <60 mm Hg. Shock was defined as hypotension associated with tissue hypoperfusion or the need of vasopressors to maintain vital organ functions. Vascular complications were those associated with surgery-related bleeding or any lesion of arteries or veins of the graft. Biliary complications were those related to stenosis, leak or collection in the biliary tree. Renal complications were any urological problem related to the transplanted kidney. Complications related to the use of steroids/immunosuppressors were as follows: hyperglycaemia, high blood pressure, osteopenia, myopathy, psychosis, ARF associated with high levels of calcineurin inhibitors with or without any other cause of renal failure, dyslipidaemia, hirsutism, gingival hyperplasia, neurotoxicity, hyperuricaemia, cytopenias and severe diarrhoea [33] . Hepatitis C infection was treated with interferon and ribavirin before transplantation only in patients with Child-Pugh A cirrhosis (six out of the 60 patients treated with LT). Hepatitis C recurrence after transplantation was treated with interferon and ribavirin in patients with severe recurrence as indicated by clinical and histological criteria (17 of the 60 LT patients and only one of the 20 CLKT patients). Hepatitis B infection was treated with lamivudine before transplantation and a combination of lamivudine and antihepatitis B immunoglobulin after transplantation.
Statistics
Student's T-test or Mann-Whitney test was used to compare continuous variables. Categorical variables were analysed using the Chi-square test or Fisher test as appropriate. Probability of survival was calculated using the Kaplan-Meier method, and curves were compared with the log rank test. Results are presented as mean ± standard deviation unless otherwise specified. All reported P-values are two-tailed, and values of <0.05 were considered statistically significant, except for the univariate analysis of survival where a P-values <0.1 was considered as significant. All statistical analysis was performed using the SPSS 14.0 program for Windows (SPSS, Chicago, IL).
Results
Baseline characteristics of the patients Table 1 shows baseline characteristics of patients included in the study at the time of transplantation. Causes of chronic kidney disease in the 20 patients treated with CLKT were chronic kidney rejection after renal transplantation in 12 patients (in 10 patients confirmed by kidney biopsy), glomerulonephritis in six (IgA glomerulonephritis in four and membranous nephropathy and focal segmental glomerulosclerosis in one patient each, all confirmed by kidney biopsy) and unknown in two patients. While all patients in the CLKT group had chronic kidney disease stages 3-5, only three (5%) of patients in the LT had impairment of renal function at the time of transplantation. Causes of renal failure in these patients were diuretic therapy, type 1 HRS and acute tubular necrosis in one patient each. Mean pretransplant serum creatinine values in these three patients were 1.73 ± 0.3 mg/dL.
Renal failure after transplantation
After transplantation, ARF occurred in 11 (55%) patients in the CLKT group during hospitalisation and in 13 (65%) patients during the first 6 months of follow-up (Table 2 ). In the LT group, the incidence of ARF was 35% during hospitalisation and 70% during the first 6 months of follow-up (P = ns vs CLKT). Five patients (25%) needed renal replacement therapy within the first 6 months after transplant compared to only two patients treated with LT (3.3%) (P = 0.009).
Despite the similar incidence of ARF in both groups, the causes were markedly different ( Table 2 ). In the CLKT group, 20 episodes of ARF occurred, 50% being due to acute tubular necrosis (six episodes) or rejection (four episodes). By contrast, in the LT group, 67% of the 62 episodes of ARF were attributed to toxicity by calcineurin inhibitors as suggested by increased serum levels of the drugs and lack of other causes of renal failure. The outcome of renal function at 6 months was similar between both groups. Mean serum creatinine at 6 months after transplantation was 1.48 ± 0.7 mg/dL in CLKT group and 1.40 ± 0.4 mg/dL in LT patients (P = ns) (Figure 1 ). The prevalence of chronic kidney disease in the CLKT group 6 months after transplantation was 25% compared to 13% in the LT group (P = ns).
Complications after transplantation Table 3 shows the complications observed within the first 6 months after transplantation in the two study groups. Infectious complications were significantly more frequent in CLKT patients than in LT patients during hospitalisation. At 6 months after transplantation, the incidence of infection was no longer significantly different between the two groups. Shock was more frequent in CLKT patients than in LT patients due to a higher frequency of septic shock that occurred in 15% of patients receiving CLKT versus none of the patients in the LT group. Blood transfusion requirements were greater in patients treated with CLKT patients compared to the LT group. This was mainly due to higher transfusion requirements during the surgical procedure (a median of 5 units for CLKT vs 4 units for LT, P = 0.031).
Complications associated with immunosuppressive therapy were common in both groups of patients. Hyperglycaemia or impairment of previous diabetes mellitus occurred in 81 and 77% of patients, respectively. De novo hypertension occurred in 67% of patients in the LT group vs 45% of patients receiving a CLKT (P = ns). ARF associated with high plasma levels of calcineurin inhibitors occurred in 48% of patients in the LT group vs 5% of patients in the CLKT group (P < 0.001). Dyslipidaemia, neurotoxicity and transient hypomagnesaemia occurred in <15% of patients. Acute liver rejection rate was similar in CLKT and LT recipients (seven patients -35% and 27 patients -45% at 6 months, respectively, P = ns). Only four patients (20%) receiving CLKT suffered kidney rejection. Kidney rejection occurred in two of the three patients with positive cross-match and in only two of the 17 patients with negative cross-match (P = 0.08). All episodes of liver or kidney rejection responded to treatment, in no case leading to graft failure. Liver and kidney rejection occurred simultaneously in only three patients.
The modification of the immunosuppressive protocols after the year 2000 was associated with a slightly higher frequency of liver rejection (P = 0.04) but not kidney rejection in patients treated with CLKT. No significant changes were observed in the frequency of liver rejection in patients treated with LT.
Overall surgical reinterventions were more frequent in the CLKT group (45 vs 18%, P = 0.034). The higher rate of reinterventions in the CLKT group was due to urological complications associated with the transplanted kidney, which developed in half of patients receiving a CLKT. Main causes of urological reintervention were bleeding and ureteral stenosis. Vascular and biliary complications occurred at a similar rate in both groups during follow-up.
Patients receiving CLKT had a longer stay in ICU and total longer in-hospital stay than patients receiving LT (median time, 7 vs 5 days and 29 vs 21 days, respectively, P = 0.037 and P = 0.01).
The frequency of complications after transplantation was similar between patients with stages 3-4 of chronic kidney disease and those with stage 5. When patients transplanted during the second half of the study period were compared to those transplanted within the first half, significant differences were observed only in the need for transfusion requirements but not in the frequency of other postoperative complications.
Graft survival
There was no primary graft failure (liver or kidney grafts) in either group. Actuarial liver graft survival was 80 and 95% for CLKT and LT, respectively, at 1 year (P = 0.038) and 75 and 87%, respectively, at 3 years (P = ns). One patient from the LT group required retransplantation for cirrhosis due to recurrent hepatitis C infection 2 years after transplantation. Development of cirrhosis due to recurrent hepatitis C infection occurred in one patient from the CLKT group and nine from the LT group (P = 0.4).
No CLKT patients reached dialysis at 3 years. No CLKT patients required kidney retransplantation during the 3-year follow-up.
Survival
Patients treated with CLKT had a 1-year survival that was slightly lower than that of patients treated with LT (80 vs 97%, respectively, P = 0.014). The probability of survival at 3 years was also lower in the CLKT group, yet the difference between the two groups did not reach statistical significance (75 and 88%, respectively, P = ns) (Figure 2 ).
Causes of death in patients with CLKT were infectious complications in two patients and cerebrovascular accident and respiratory failure in one patient each. Causes of death in patients with LT were infectious complications in two patients and hepatocellular carcinoma, laryngeal carcinoma, multiorgan failure after retransplantation, amyotrophic lateral sclerosis and acute pancreatitis in one patient each.
Factors associated with an increased risk of death at 1 year in patients treated with CLKT were serum bilirubin and MELD score before transplantation and development of shock, infections and ARF during hospitalisation. Both short-and long-term survival of patients with stage 5 chronic kidney disease were similar to those of patients with stages 3-4 (P = ns). The modification of the immunosuppressive protocols during the study period did not have a significant impact on patient survival. Likewise, there were no significant differences in the survival of patients transplanted within the first part of the study period and that of patients transplanted within the second part of the study period.
Discussion
The main findings of the current study are that CLKT in patients with cirrhosis and associated chronic kidney disease can be performed with an acceptable rate of postoperative complications and a relatively high survival considering that these patients have a combination of severe chronic kidney and liver disease before transplantation and are submitted to two solid organ transplants. In fact, in the current study, the frequency of postoperative complications was only moderately higher and 1-year survival moderately lower than those observed in a contemporary group of patients with cirrhosis of similar severity but without chronic kidney disease submitted to LT alone. Three-year survival, although slightly lower in the group of patients treated with CLKT, was not significantly different among the two groups.
There are important issues about the design of this study that deserve discussion. First, the validity of the conclusions is limited by the fact that this is a retrospective study. Nevertheless, it should be pointed out that the most important variables analysed were collected prospectively in our transplant database. On the other hand, it would be very difficult to perform a prospective study of patients treated with CLKT because of the low number of patients submitted to this procedure annually. Second, when designing this study, it was considered important to compare the outcome of patients treated with CLKT to that of another group of transplanted patients in order to assess the significance of the findings. The use of the whole population of patients submitted to LT during the same period was not considered appropriate because the possible differences in outcome could be secondary to differences in the severity of cirrhosis at the time of transplantation between patients treated with CLKT and those treated with LT alone. A comparative group of patients with chronic kidney disease submitted to LT alone was not feasible because all patients with cirrhosis and advanced chronic kidney disease are considered candidates for CLKT. Therefore, it was felt that a possible comparative group would be that of a contemporary series of patients submitted to LT alone but matched for the severity of cirrhosis. This group is also not ideal because patients do not have chronic kidney disease and are submitted to only one solid organ transplantation and there might be some differences that are difficult to account for between this group and that of patients treated with CLKT, such as the aetiology of cirrhosis or the different immunosuppressive protocols. Nevertheless, this last approach was considered better than the other two approaches and could allow for some orientative assessment of the outcome in patients treated with CLKT.
Patients receiving a CLKT had a high frequency of infections and intraoperative bleeding and long ICU and hospital stays. This increased frequency of complications was probably responsible for the lower 1-year survival of patients treated with CLKT compared to that of patients treated with LT (80 vs 97%, respectively). The increased rate of infections in patients with CLKT deserves a specific comment because infections were associated with 1-year mortality in the multivariate analysis. Our results are in keeping with those of previous studies suggesting a major role for sepsis on early posttransplantation mortality in patients treated with CLKT [7, 9, 25, 29] . Moreover, infections are a more common cause of death in recipients of CLKT compared to recipients of kidney transplant alone [8] . Several mechanisms may be accounted for by this increased frequency of severe infections in patients treated with CLKT, including more aggressive immunosuppressive regimens (i.e. induction therapy, addition of MMF), pretransplant immunosuppresion in some patients due to previous kidney grafts, presence of associated severe renal failure and greater surgical manipulation compared to LT alone. Whichever the mechanism responsible for the increased frequency of severe infections is, patients submitted to CLKT should be carefully evaluated for the presence of infections and antibiotic therapy should be instituted early when there is any suspicion of infection. Patients treated with CLKT also had a relatively high incidence of surgical complications, particularly bleeding and need for reintervention. This has been reported in previous studies and is probably related to the increased surgical manipulation required for CLKT with respect to LT alone [7, 9] .
Patients from both CLKT and LT groups had a high and similar incidence of ARF during the 6-month period after transplantation (65 vs 70%, respectively), yet peak serum creatinine concentration and need for dialysis were higher in patients from the CLKT group compared to those in the LT group, indicating a greater severity of renal failure in the CLKT group. This is also supported by the fact that ARF was an independent risk factor of early mortality in CLKT patients. Causes of ARF were markedly different among groups. A high percentage (69%) of ARF in the LT group was attributed to calcineurin inhibitors, whereas most episodes of ARF in patients treated with CLKT were due either to acute tubular necrosis or rejection. Nevertheless, as shown by the very similar serum creatinine levels at 6 months, the causes of ARF had little impact on the subsequent recovery of renal function.
Survival of patients with cirrhosis and chronic kidney disease treated with CLKT was very good and only slightly lower than that of patients with cirrhosis of similar severity treated with LT alone (Figure 2 ). It should be noted, however, that not all patients treated with CLKT had very advanced kidney disease, as few patients had stage 3 kidney disease. This survival was similar to that reported in previous studies of patients treated with CLKT that included not only patients with cirrhosis but also patients with metabolic liver diseases without liver failure or polycystic liver and kidney disease [2, 4, 5, 9, 12, 16, 17, 19, [22] [23] [24] [26] [27] [28] . It is interesting to note that baseline MELD score was an independent predictive factor of posttransplant survival in the CLKT group. Graft survival was excellent and comparable to other studies. Liver rejection, as well as the kidney rejection rate, was similar to those reported in other studies [5, 7, 8, 12, 16, 17, 22, 24, 25, 28] .
There is a final aspect of the current investigation that needs to be discussed. The current series of patients treated with CLKT does not include patients with HRS. Treatment of patients with cirrhosis and HRS with CLKT instead of LT alone is controversial because it increases the number of kidneys used in patients with cirrhosis and may increase the cost of therapy and be associated with higher morbidity and mortality after transplantation [12, 15] . The reason for the lack of patients with HRS treated with CLKT in the current series is that in our centre, patients with HRS are treated before transplantation with the combination of terlipressin, a vasopressin analogue, and albumin [35, 36] . This strategy has the advantage over CLKT of improving renal function before transplantation, which may be associated with an improved outcome after transplantation [37] . Moreover, this approach does not increase the number of kidneys required for treatment of patients with cirrhosis and renal failure.
In conclusion, the results of this study show that patients with cirrhosis and chronic kidney disease can be submitted to CLKT with an acceptable rate of postoperative complications and have a high survival rate. Therefore, CLKT is an excellent approach to management of patients with cirrhosis and chronic kidney disease.
